-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Centessa Pharmaceuticals plc quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2022 to 2023.
- Centessa Pharmaceuticals plc Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was $434K.
- Centessa Pharmaceuticals plc annual Deferred Income Tax Expense (Benefit) for 2023 was -$26.5M, a 829% decline from 2022.
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)